Osamu Tetsu

Medicine · Health Sciences

19h-index5.8kcitations39works0.02yr avg
OpenAlex↗ORCID↗Google Scholar↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

Cancer-related Molecular Pathways(8), Salivary Gland Tumors Diagnosis and Treatment(6), Lung Cancer Treatments and Mutations(5), PI3K/AKT/mTOR signaling in cancer(5), Ubiquitin and proteasome pathways(5)

Publications39 total

[Transmission of SARS-CoV-2 through contact with a SARS-CoV-2-infected individual in the presymptomatic or asymptomatic state in Japan: A case series].
PubMed·2021· 3 cited
Abstract 3104: Establishment of an oral tongue squamous cell carcinoma cell line from a never-smoking patient
Cancer Research·2018
Identifying Neurofibromin Specific Regulatory Nodes for Therapeutic Targeting in NF1
2017
ETS‐targeted therapy: can it substitute for MEK inhibitors?
Clinical and Translational Medicine·2017· 36 citedOpen Access
Establishment and characterization of an oral tongue squamous cell carcinoma cell line from a never-smoking patient
Oral Oncology·2017· 12 cited
Abstract 293: EGFR inhibition generates drug-tolerant persister cells by blocking AKT activity and thus inactivating Ets-1 function
Cancer Research·2016
Drug Resistance to EGFR Inhibitors in Lung Cancer
Chemotherapy·2016· 99 citedOpen Access
AKT inactivation causes persistent drug tolerance to EGFR inhibitors
Pharmacological Research·2015· 29 cited
Resistance to EGFR-targeted therapy by Ets-1 inactivation
Cell Cycle·2015· 4 citedOpen Access
ETS1 inactivation causes innate drug resistance to EGFR inhibitors
Molecular & Cellular Oncology·2015· 7 citedOpen Access
EGFR inhibition evokes innate drug resistance in lung cancer cells by preventing Akt activity and thus inactivating Ets-1 function
Proceedings of the National Academy of Sciences·2015· 102 citedOpen Access
Inhibition of ERK1/2 down-regulates the Hippo/YAP signaling pathway in human NSCLC cells
Oncotarget·2015· 101 citedOpen Access
Fatty Acid Binding Protein 7 Is a Molecular Marker in Adenoid Cystic Carcinoma of the Salivary Glands: Implications for Clinical Significance
Translational Oncology·2014· 23 citedOpen Access
c-Kit Expression is Rate-Limiting for Stem Cell Factor-Mediated Disease Progression in Adenoid Cystic Carcinoma of the Salivary Glands
Translational Oncology·2014· 20 citedOpen Access
TP53 and CDKN2a mutations in never‐smoker oral tongue squamous cell carcinoma
The Laryngoscope·2014· 34 cited
Cyclin D1 harboring the T286I mutation promotes oncogenic activation in endometrial cancer
Oncology Reports·2013· 15 citedOpen Access
Abstract 1748: Cyclin D1 harboring T286I mutation promotes oncogenic activation in endometrial cancer.
Cancer Research·2013
Mutations in the c-Kit Gene Disrupt Mitogen-Activated Protein Kinase Signaling during Tumor Development in Adenoid Cystic Carcinoma of the Salivary Glands
Neoplasia·2010· 46 citedOpen Access
Abstract B10: Genetic profiling reveals cross-contamination and misidentification of six adenoid cystic carcinoma cell lines
Clinical Cancer Research·2010
Abstract 351: Mutations of genes in the c-Kit receptor tyrosine kinase signaling pathway are inactive in adenoid cystic carcinoma of the salivary glands: Implications for c-Kit targeted therapy
Cancer Research·2010
page 1 of 2Next →

Frequent Co-authors

Frank McCormick(20), Janyaporn Phuchareon(14), David W. Eisele(12), Annemieke van Zante(5), Masamoto Kanno(4), Pablo Rodriguez‐Viciana(3), Katherine A. Rauen(3), Rieko Kanno(3), Jonathan M. Woo(2), Matthew J. Hangauer(2), Hiroto Ishihara(2), Masaya Kamiyasu(2), Hiroko Inoue(2), Annie Chou(2), Darren P. Cox(2), Richard C. Jordan(2), Chase M. Heaton(2), Jonathan B. Overdevest(2), Hiroyoshi Furukawa(2), Tsuyoshi Hara(2)